{"id":997204,"date":"2026-08-21T08:09:51","date_gmt":"2026-08-21T12:09:51","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-announces-oral-presentations-at-two-upcoming-medical-conferences-2\/"},"modified":"2026-08-21T08:09:51","modified_gmt":"2026-08-21T12:09:51","slug":"belite-bio-announces-oral-presentations-at-two-upcoming-medical-conferences-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-announces-oral-presentations-at-two-upcoming-medical-conferences-2\/","title":{"rendered":"Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p>SAN DIEGO, Aug.  21, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PoMgAmc7t2_ugbzvH3vpHOIPunXpEGvWu8x_t8-4cxylN5pPIbZOF3kEgvcgT9pi3FLArVKMt8aQ88roJc5rpt4zupex9ZrR2oGdd5L-cibS9hIjmHpayWYASetEKo4um99mztl4Z26DBim50XA1GgxNXt0C-_TXfP4kwTZxHm_3rMnFOEhLm0KoDOIxwsZ4nquBPJCuCGf1qNUoKa0TNX7RceL9niUPdSDJT1ETFyA=\" rel=\"nofollow\" target=\"_blank\">Belite Bio<\/a>, Inc (NASDAQ: BLTE) (\u201cBelite Bio<sup>\u00ae<\/sup>\u201d or the \u201cCompany\u201d), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its data will be presented at the Schweizerische Ophthalmologische Gesellschaft (SOG) Annual Congress being held on August 26-28, 2026, in Lausanne, Switzerland and the 19th Asia-Pacific Vitreo-retina Society (APVRS) Congress being held on August 28-30, 2026, in Gold Coast, Australia.<\/p>\n<p>\n        <strong><br \/>\n          <u>SOG Presentation Details<\/u><br \/>\n        <\/strong><br \/>\n        <br \/>\n        <strong>Session: <\/strong>Free Communications I \u2013 Retina Vitreous<br \/><strong>Title:\u00a0<\/strong>Results from the Phase 3 Dragon Study of Tinlarebant for Adolescent and Adult Stargardt Disease<br \/><strong>Presenter:\u00a0<\/strong>Dr.med. Hoai Viet Tran, FMH, FEBO, Consultant Physician, Head of the Ocular Genetics &amp; Gene Therapy Unit, Department of Ophthalmology, University of Lausanne, H\u00f4pital ophtalmique Jules-Gonin, Fondation Asile des aveugles<br \/><strong>Date and Time:\u00a0<\/strong>August 27, 2026, 8:30 \u2013 8:40 p.m. CEST<br \/><strong>Location:\u00a0<\/strong>SwissTech Convention Center, EPFL Campus, Lausanne, Switzerland<\/p>\n<p>\n        <strong><br \/>\n          <u>APVRS Presentation Details<\/u><br \/>\n        <\/strong><br \/>\n        <br \/>\n        <strong>Session:\u00a0<\/strong>Late Breaking Symposium<br \/><strong>Title:\u00a0<\/strong>New Insights from the DRAGON Study of Tinlarebant for Stargardt\u2019s Disease<br \/><strong>Presenter:\u00a0<\/strong>Quan Dong Nguyen, M.D., Professor of Ophthalmology at the Byers Eye Institute and Professor of Pediatrics and Professor of Medicine (Immunology and Rheumatology), Stanford University School of Medicine<br \/><strong>Date and Time:\u00a0<\/strong>August 30, 2026, 8:00 \u2013 8:08 a.m. AEST<br \/><strong>Location:\u00a0<\/strong>Gold Coast Convention &amp; Exhibition Centre<\/p>\n<p>\n        <strong>Session:\u00a0<\/strong>Rapid Fire 6 &#8211; Myopia (1), Retina (Surgical) (1) and Retina (Medical) (6)<br \/><strong>Title:\u00a0<\/strong>Topline Results from the Phase 3 DRAGON Study of Tinlarebant for Adolescent Stargardt\u2019s Disease<br \/><strong>Presenter:\u00a0<\/strong>John Grigg, M.D., Professor of Clinical and Experimental Ophthalmology and Head of the Discipline of Ophthalmology at The University of Sydney&#8217;s Save Sight Institute, Consultant, Sydney Eye Hospital and The Children&#8217;s Hospital Westmead<br \/><strong>Date and Time:\u00a0<\/strong>August 30, 2026, 12:10-12:15 p.m. AEST<br \/><strong>Location:\u00a0<\/strong>Gold Coast Convention &amp; Exhibition Centre<\/p>\n<p>\n        <strong>Session:\u00a0<\/strong>Inherited Retinal Diseases and Electrophysiology<br \/><strong>Title:\u00a0<\/strong>Update on ABCA4-Retinopathy Therapy: Therapeutic Trials in Japan<br \/><strong>Presenter:\u00a0<\/strong>Kaoru Fujinami, M.D., Ph.D., Professor of the National Institute of Sensory Organs at National Hospital Organization Tokyo Medical Center, and Honorary Professor of the University College London Institute of Ophthalmology.<br \/><strong>Date and Time:\u00a0<\/strong>August 29, 2026, 11:36-11:48 a.m. AEST<br \/><strong>Location:\u00a0<\/strong>Gold Coast Convention &amp; Exhibition Centre<\/p>\n<p>\n        <strong>About Tinlarebant (a\/k\/a LBS-008)<\/strong>\n      <\/p>\n<p>Tinlarebant is a novel oral therapy that is intended to reduce the accumulation of vitamin A-based toxins (known as bisretinoids) that cause retinal disease in Stargardt disease type 1 (STGD1) and also contribute to disease progression in geographic atrophy (GA), or advanced dry age-related macular degeneration (AMD). Bisretinoids are by-products of the visual cycle, which is dependent on the supply of vitamin A (retinol) to the eye. Tinlarebant works by reducing and maintaining levels of serum retinol binding protein 4 (RBP4), the sole carrier protein for retinol transport from the liver to the eye. By modulating the amount of retinol entering the eye, tinlarebant reduces the formation of bisretinoids. Tinlarebant has been granted Breakthrough Therapy Designation, Fast Track Designation, and Rare Pediatric Disease Designation in the U.S., Orphan Drug Designation in the U.S., Europe, Japan, and Switzerland, and Sakigake Designation in Japan for the treatment of STGD1.<\/p>\n<p>\n        <strong>About Stargardt Disease<\/strong>\n      <\/p>\n<p>STGD1 is the most common inherited macular dystrophy in both adults and children. The disease is caused by mutations in a retina-specific gene (ABCA4), which results in progressive accumulation of bisretinoids leading to retinal cell death and progressive loss of central vision. The fluorescent properties of bisretinoids and the development of high-resolution retinal imaging systems have helped ophthalmologists identify and monitor disease progression. Currently, there are no approved treatments for STGD1.<\/p>\n<p>\n        <strong>About Belite Bio<\/strong>\n      <\/p>\n<p>Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease type 1 (STGD1) and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite Bio\u2019s lead candidate, tinlarebant, is an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye. The Company has completed a Phase 3 trial (DRAGON) in adolescent and adult subjects with STGD1, which met its primary endpoint, and the drug is currently being evaluated in a Phase 2\/3 trial (DRAGON II) in adolescent and adult subjects with STGD1 and a Phase 3 trial (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook, or visit us at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=z5ePy4eGr5aYxMKVrn_rgA7m0KvUyaMUjv1RBrOXWCxioXYe4P11MXOE949oTvf8ts-BGebbqVIAD84Xf3SGtCwP3k_I2liAoYQHor4PaoE=\" rel=\"nofollow\" target=\"_blank\">www.belitebio.com<\/a>.<\/p>\n<p>\n        <strong>Media and Investor Relations Contact:<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RGihLW5LiyVENb3KdHbXEhJdRCay8KPaB6PBbmyP3t4DieRppd79lNvbe799rOkf3r7Ql-FygY0Ljq7DdSQdzwoCTGvzIPVOiXg2hMJpRuk=\" rel=\"nofollow\" target=\"_blank\">ir@belitebio.com<\/a>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNDAyMCM3Nzg3Mzk5IzIyMzM3MzI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OWM5YzQwYjgtN2M4Mi00NjUyLWJlYzItMjg2YWJiMzM2M2M4LTEyNDUyODUtMjAyNi0wOC0yMS1lbg==\/tiny\/Belite-Bio-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, Aug. 21, 2026 (GLOBE NEWSWIRE) &#8212; Belite Bio, Inc (NASDAQ: BLTE) (\u201cBelite Bio\u00ae\u201d or the \u201cCompany\u201d), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its data will be presented at the Schweizerische Ophthalmologische Gesellschaft (SOG) Annual Congress being held on August 26-28, 2026, in Lausanne, Switzerland and the 19th Asia-Pacific Vitreo-retina Society (APVRS) Congress being held on August 28-30, 2026, in Gold Coast, Australia. SOG Presentation Details Session: Free Communications I \u2013 Retina VitreousTitle:\u00a0Results from the Phase 3 Dragon Study of Tinlarebant for Adolescent and Adult Stargardt DiseasePresenter:\u00a0Dr.med. Hoai Viet Tran, FMH, FEBO, Consultant Physician, Head of the Ocular Genetics &amp; Gene Therapy &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-announces-oral-presentations-at-two-upcoming-medical-conferences-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-997204","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-announces-oral-presentations-at-two-upcoming-medical-conferences-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, Aug. 21, 2026 (GLOBE NEWSWIRE) &#8212; Belite Bio, Inc (NASDAQ: BLTE) (\u201cBelite Bio\u00ae\u201d or the \u201cCompany\u201d), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its data will be presented at the Schweizerische Ophthalmologische Gesellschaft (SOG) Annual Congress being held on August 26-28, 2026, in Lausanne, Switzerland and the 19th Asia-Pacific Vitreo-retina Society (APVRS) Congress being held on August 28-30, 2026, in Gold Coast, Australia. SOG Presentation Details Session: Free Communications I \u2013 Retina VitreousTitle:\u00a0Results from the Phase 3 Dragon Study of Tinlarebant for Adolescent and Adult Stargardt DiseasePresenter:\u00a0Dr.med. Hoai Viet Tran, FMH, FEBO, Consultant Physician, Head of the Ocular Genetics &amp; Gene Therapy &hellip; Continue reading &quot;Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-announces-oral-presentations-at-two-upcoming-medical-conferences-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-21T12:09:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNDAyMCM3Nzg3Mzk5IzIyMzM3MzI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-announces-oral-presentations-at-two-upcoming-medical-conferences-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-announces-oral-presentations-at-two-upcoming-medical-conferences-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences\",\"datePublished\":\"2026-08-21T12:09:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-announces-oral-presentations-at-two-upcoming-medical-conferences-2\\\/\"},\"wordCount\":734,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-announces-oral-presentations-at-two-upcoming-medical-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgxNDAyMCM3Nzg3Mzk5IzIyMzM3MzI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-announces-oral-presentations-at-two-upcoming-medical-conferences-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-announces-oral-presentations-at-two-upcoming-medical-conferences-2\\\/\",\"name\":\"Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-announces-oral-presentations-at-two-upcoming-medical-conferences-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-announces-oral-presentations-at-two-upcoming-medical-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgxNDAyMCM3Nzg3Mzk5IzIyMzM3MzI=\",\"datePublished\":\"2026-08-21T12:09:51+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-announces-oral-presentations-at-two-upcoming-medical-conferences-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-announces-oral-presentations-at-two-upcoming-medical-conferences-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-announces-oral-presentations-at-two-upcoming-medical-conferences-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgxNDAyMCM3Nzg3Mzk5IzIyMzM3MzI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgxNDAyMCM3Nzg3Mzk5IzIyMzM3MzI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/belite-bio-announces-oral-presentations-at-two-upcoming-medical-conferences-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-announces-oral-presentations-at-two-upcoming-medical-conferences-2\/","og_locale":"en_US","og_type":"article","og_title":"Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences - Market Newsdesk","og_description":"SAN DIEGO, Aug. 21, 2026 (GLOBE NEWSWIRE) &#8212; Belite Bio, Inc (NASDAQ: BLTE) (\u201cBelite Bio\u00ae\u201d or the \u201cCompany\u201d), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its data will be presented at the Schweizerische Ophthalmologische Gesellschaft (SOG) Annual Congress being held on August 26-28, 2026, in Lausanne, Switzerland and the 19th Asia-Pacific Vitreo-retina Society (APVRS) Congress being held on August 28-30, 2026, in Gold Coast, Australia. SOG Presentation Details Session: Free Communications I \u2013 Retina VitreousTitle:\u00a0Results from the Phase 3 Dragon Study of Tinlarebant for Adolescent and Adult Stargardt DiseasePresenter:\u00a0Dr.med. Hoai Viet Tran, FMH, FEBO, Consultant Physician, Head of the Ocular Genetics &amp; Gene Therapy &hellip; Continue reading \"Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-announces-oral-presentations-at-two-upcoming-medical-conferences-2\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-21T12:09:51+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNDAyMCM3Nzg3Mzk5IzIyMzM3MzI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-announces-oral-presentations-at-two-upcoming-medical-conferences-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-announces-oral-presentations-at-two-upcoming-medical-conferences-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences","datePublished":"2026-08-21T12:09:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-announces-oral-presentations-at-two-upcoming-medical-conferences-2\/"},"wordCount":734,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-announces-oral-presentations-at-two-upcoming-medical-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNDAyMCM3Nzg3Mzk5IzIyMzM3MzI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-announces-oral-presentations-at-two-upcoming-medical-conferences-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-announces-oral-presentations-at-two-upcoming-medical-conferences-2\/","name":"Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-announces-oral-presentations-at-two-upcoming-medical-conferences-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-announces-oral-presentations-at-two-upcoming-medical-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNDAyMCM3Nzg3Mzk5IzIyMzM3MzI=","datePublished":"2026-08-21T12:09:51+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-announces-oral-presentations-at-two-upcoming-medical-conferences-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-announces-oral-presentations-at-two-upcoming-medical-conferences-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-announces-oral-presentations-at-two-upcoming-medical-conferences-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNDAyMCM3Nzg3Mzk5IzIyMzM3MzI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgxNDAyMCM3Nzg3Mzk5IzIyMzM3MzI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/belite-bio-announces-oral-presentations-at-two-upcoming-medical-conferences-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/997204","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=997204"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/997204\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=997204"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=997204"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=997204"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}